Reoperation after transcervical thymectomy for myasthenia gravis

Area of Science:

• Neurology
• Surgical Oncology

Background:

• Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions.
• Thymectomy is a common treatment for MG, aiming to remove the thymus gland where T-cells involved in the autoimmune process mature.
• Incomplete thymectomy can lead to persistent MG symptoms and necessitate further intervention.

Purpose of the Study:

• To evaluate the outcomes of reoperations for patients with nonthymomatous myasthenia gravis (MG) who had undergone initial transcervical thymectomy.
• To investigate the presence and significance of residual thymus tissue after transcervical thymectomy.

Main Methods:

• Retrospective analysis of 137 thymectomized patients with nonthymomatous MG.
• Focus on six patients who underwent reoperation via median sternotomy after an ineffective initial transcervical thymectomy.
• Histopathological examination of resected thymus tissue.

Main Results:

• All six reoperation patients had residual thymus tissue, averaging 19 gm.
• Three patients experienced favorable postoperative courses.
• Three patients had unfavorable courses, with two on high-dose steroid therapy prior to reoperation.

Conclusions:

• Total thymectomy via the transcervical approach is technically challenging and often incomplete.
• Reoperation for residual thymus in MG patients can lead to clinical improvement in some cases.
• Preoperative steroid use may influence the outcome of reoperation for MG.